Al-Batran SE, et al. - To establish the effectiveness and safety of the docetaxel-based triplet, fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) for locally advanced, resectable tumors as a perioperative therapy, investigators conducted a controlled, open-label, phase 2/3 trial, including 716 patients diagnosed with advanced clinical stage cT2 or greater or nodal positive stage (cN+), or both, without any evident distant metastases. Perioperative FLOT improved survival in locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma vs perioperative ECF/ECX. The number of patients with related serious adverse events (including those occurring during hospital stay for surgery) was comparable across the two groups.